News

RedDress Enhances Wound Care Access Through New Partnership

RedDress Enhances Wound Care Access Through New Partnership

RedDress Announces Strategic Partnership with Legacy Medical Consultants

RedDress, a pioneering company in wound management technology, has taken an innovative step by partnering with Legacy Medical Consultants to expand the availability of its ActiGraft wound therapy across the United States. This partnership is poised to significantly enhance access to treatment for chronic wounds, which are often considered a silent epidemic affecting millions of individuals annually.

Enhancing Access to Advanced Wound Care

The exclusive distribution agreement allows Legacy Medical Consultants (LMC) to take charge of sales, marketing, and customer support activities for ActiGraft. This collaboration aims to streamline access to autologous blood-clot treatment within diverse healthcare settings, such as hospitals, outpatient clinics, and veterans' affairs facilities. By doing so, RedDress and LMC are committed to addressing the critical demand for improved wound care solutions.

Understanding Chronic Wounds and Their Impact

Chronic wounds affect roughly 6.5 million people each year, driven by factors such as diabetes, obesity, and an aging population. The necessity for effective wound care solutions has never been more urgent. Traditional methods often fall short, making treatments like ActiGraft essential for re-initiating the body’s natural healing processes.

ActiGraft: Revolutionizing Wound Treatment

ActiGraft is an innovative autologous graft that uses a patient's own blood to promote healing. It replaces dysfunctional extracellular matrix components in stalled wounds, providing a foundation for the body’s healing cascade to resume effectively. Notably, ActiGraft can be beneficial for patients on blood thinners or with exposed bone, making it a versatile option in challenging clinical scenarios.

Voices from Leadership

Alon Kushnir, CEO and Co-Founder of RedDress, expressed enthusiasm about this partnership, highlighting that the expertise of LMC’s team complements RedDress's advanced graft technology perfectly. He believes this strategic alliance will greatly enhance ActiGraft’s reach and patient outcomes, ultimately delivering innovative and effective care to those struggling with non-healing wounds.

Commitment to Improving Patient Outcomes

Jonathan Knutz, Chief Executive Officer of LMC, aligns with this vision. Knutz emphasizes the importance of combating chronic wounds, asserting that patients should have access to the most effective treatments available. He views this partnership with RedDress as pivotal in broadening treatment options for patients and improving their overall quality of life.

Availability of ActiGraft

Healthcare facilities can now order ActiGraft through LMC’s Customer Service Department. Existing customers of RedDress will experience a seamless transition without any interruption to their supply or support services. This smooth integration is essential for maintaining the continuity of care that patients urgently need.

About Legacy Medical Consultants

Legacy Medical Consultants is dedicated to enhancing patient care through innovative solutions in wound management. Their team focuses on addressing unmet clinical needs while providing high-quality products and services to healthcare providers. This commitment positions LMC as a leader in the evolving field of wound care.

About RedDress

RedDress is a forward-thinking biomedical company centered on developing patient-centric wound care solutions. Their expertise in autologous technology not only underscores their innovation but also reflects their dedication to improving clinical outcomes. The company holds multiple patents on its blood clot technology and continuously seeks to advance the field of chronic wound management.

Frequently Asked Questions

What is the focus of the partnership between RedDress and Legacy Medical Consultants?

The partnership aims to improve access to ActiGraft wound therapy across various healthcare settings, addressing the needs of chronic wound patients.

How does ActiGraft work?

ActiGraft utilizes a patient’s own blood to create a clot that helps support natural healing processes in chronic wounds.

Who can benefit from ActiGraft treatment?

ActiGraft is suitable for patients, including those on blood thinners or with exposed tissue, providing a versatile solution in wound management.

How can healthcare providers order ActiGraft?

Providers can place orders through Legacy Medical Consultants' Customer Service Department to access ActiGraft promptly.

What commitment does RedDress make to patient care?

RedDress is focused on transforming wound care through patient-centric innovations and ensuring access to effective treatments for chronic wounds.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading